{"id":2823,"date":"2008-07-08T08:58:36","date_gmt":"2008-07-08T15:58:36","guid":{"rendered":"http:\/\/www.carlsbadistan.com\/?p=2823"},"modified":"2008-07-08T08:58:41","modified_gmt":"2008-07-08T15:58:41","slug":"fda-approval-for-invitrogen-test","status":"publish","type":"post","link":"http:\/\/www.carlsbadistan.com\/?p=2823","title":{"rendered":"FDA Approval For Invitrogen Test"},"content":{"rendered":"<p>A new genetic test from <strong><a href=\"http:\/\/www.invitrogen.com\/\" target=\"_blank\">Invitrogen<\/a><\/strong> that can gauge a patient&#8217;s response to a new breast cancer drug was approved by <strong>The Food and Drug Aministration<\/strong> today, according to a story on <strong><a href=\"http:\/\/money.cnn.com\/news\/newsfeeds\/articles\/apwire\/8cd38329898b33d657c652f38872ab8c.htm\" target=\"_blank\">CNNMoney.com<\/a><\/strong>.<\/p>\n<blockquote><p><strong>Herceptin<\/strong> was the first of a new class of cancer drugs which destroy cancer cells without also killing normal cells. It works by targeting the HER-2 gene, which encourages tumor growth. However, only about 20 percent of breast cancer patients have cancer caused by the gene. . . .The <strong>Spotlight HER2 CISH<\/strong> test from Invitrogen identifies which patients are likely to respond to Herceptin based on the amount of HER-2 gene in their tumors.<\/p><\/blockquote>\n<p>Invitrogen stock was up 72 cents on the news.<\/p>\n<p><strong>[Link: <\/strong><strong><a href=\"http:\/\/money.cnn.com\/news\/newsfeeds\/articles\/apwire\/8cd38329898b33d657c652f38872ab8c.htm\" target=\"_blank\">CNNMoney.com<\/a><\/strong><strong>]<\/strong> <\/p>\n","protected":false},"excerpt":{"rendered":"<p>A new genetic test from Invitrogen that can gauge a patient&#8217;s response to a new breast cancer drug was approved by The Food and Drug Aministration today, according to a story on CNNMoney.com. Herceptin was the first of a new class of cancer drugs which destroy cancer cells without also killing normal cells. It works [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"ngg_post_thumbnail":0,"footnotes":""},"categories":[8,34],"tags":[],"_links":{"self":[{"href":"http:\/\/www.carlsbadistan.com\/index.php?rest_route=\/wp\/v2\/posts\/2823"}],"collection":[{"href":"http:\/\/www.carlsbadistan.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.carlsbadistan.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.carlsbadistan.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"http:\/\/www.carlsbadistan.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2823"}],"version-history":[{"count":0,"href":"http:\/\/www.carlsbadistan.com\/index.php?rest_route=\/wp\/v2\/posts\/2823\/revisions"}],"wp:attachment":[{"href":"http:\/\/www.carlsbadistan.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2823"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.carlsbadistan.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2823"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.carlsbadistan.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2823"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}